Literature DB >> 12142557

Identification of immune dominant cytomegalovirus epitopes using quantitative real-time polymerase chain reactions to measure interferon-gamma production by peptide-stimulated peripheral blood mononuclear cells.

Maurizio Provenzano1, Simone Mocellin, Maria Bettinotti, Jeanne Preuss, Vladia Monsurrò, Francesco M Marincola, David Stroncek.   

Abstract

The identification of HLA restricted immune dominant cytotoxic T cell (CTL) epitopes limits immune therapy. Cytomegalovirus (CMV) disease remains a significant cause of morbidity after allogeneic stem cell transplantation. Adoptive immune therapy using CTLs stimulated with immune dominant CMV pp65 peptides may be effective in preventing CMV disease, but immune dominant CMV peptides have been identified for only a few HLA class I molecules. The purpose of this study was to use a novel molecular system to establish a rapid and precise method to identify new HLA-restricted CMV epitopes. Cytomegalovirus pp65 peptides expected to bind to the HLA-24 molecule were identified with a computer algorithm. Five candidate peptides were screened by direct ex vivo stimulation of peripheral blood mononuclear cells (PBMCs) from CMV-seropositive HLA-A*2402 individuals, and quantitative real time PCR (qRT-PCR) was used to evaluate CTL responses by measuring interferon-gamma (IFN-gamma) transcripts. One of the five candidate peptides, pp65341-350 (QYDPVAALFF), induced significant quantities of IFN-gamma mRNA production after 3 hours. PBMCs from CMV-seropositive HLA-A*2402 individuals sensitized in vitro with pp65341-350 also recognized CMV-infected targets. In conclusion, the measurement of IFN-gamma mRNA by qRT-PCR can be used to detect CTL responses 3 hours after peptide stimulation of a small quantity of PBMCs. This method has an advantage over other methods used to identify immune dominant epitopes in that it does not require in vitro expansion of CTLs with cytokines or virally infected targets. As a result, this method measures naturally induced immune reactions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12142557     DOI: 10.1097/00002371-200207000-00006

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  15 in total

1.  Development of a novel, guinea pig-specific IFN-γ ELISPOT assay and characterization of guinea pig cytomegalovirus GP83-specific cellular immune responses following immunization with a modified vaccinia virus Ankara (MVA)-vectored GP83 vaccine.

Authors:  Peter A Gillis; Nelmary Hernandez-Alvarado; Josephine S Gnanandarajah; Felix Wussow; Don J Diamond; Mark R Schleiss
Journal:  Vaccine       Date:  2014-05-20       Impact factor: 3.641

2.  Measurement of cytotoxic T lymphocyte activity of human cytomegalovirus seropositive individuals by a highly sensitive coupled luminescent method.

Authors:  Henry Ogbomo; Janina Geiler; Anke Leutz; Kristina von Kietzell; Martin Michaelis; Hans Wilhelm Doerr; Jindrich Cinatl
Journal:  Med Microbiol Immunol       Date:  2009-10-08       Impact factor: 3.402

Review 3.  Global transcriptional analysis for biomarker discovery and validation in cellular therapies.

Authors:  David F Stroncek; Ping Jin; Ena Wang; Jiagiang Ren; Marianna Sabatino; Francesco M Marincola
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

4.  Sequential anti-cytomegalovirus response monitoring may allow prediction of cytomegalovirus reactivation after allogeneic stem cell transplantation.

Authors:  Sylvia Borchers; Melanie Bremm; Thomas Lehrnbecher; Elke Dammann; Brigitte Pabst; Benno Wölk; Ruth Esser; Meral Yildiz; Matthias Eder; Michael Stadler; Peter Bader; Hans Martin; Andrea Jarisch; Gisbert Schneider; Thomas Klingebiel; Arnold Ganser; Eva M Weissinger; Ulrike Koehl
Journal:  PLoS One       Date:  2012-12-13       Impact factor: 3.240

5.  Analysis of memory T lymphocyte activity following stimulation with overlapping HLA-A*2402, A*0101 and Cw*0402 restricted CMV pp65 peptides.

Authors:  Monica Ghei; David F Stroncek; Maurizio Provenzano
Journal:  J Transl Med       Date:  2005-05-26       Impact factor: 5.531

6.  Characterization of highly frequent epitope-specific CD45RA+/CCR7+/- T lymphocyte responses against p53-binding domains of the human polyomavirus BK large tumor antigen in HLA-A*0201+ BKV-seropositive donors.

Authors:  Maurizio Provenzano; Laura Bracci; Stephen Wyler; Tvrtko Hudolin; Giovanni Sais; Rainer Gosert; Paul Zajac; Giorgio Palu'; Michael Heberer; Hans H Hirsch; Giulio C Spagnoli
Journal:  J Transl Med       Date:  2006-11-10       Impact factor: 5.531

7.  Identification of HLA-A*2402-restricted HCMV immediate early-1 (IE-1) epitopes as targets for CD8+ HCMV-specific cytotoxic T lymphocytes.

Authors:  Jong-Baeck Lim; Hyun Ok Kim; Seok Hoon Jeong; Joo Eun Ha; Sunphil Jang; Sang-Guk Lee; Kyungwon Lee; David Stroncek
Journal:  J Transl Med       Date:  2009-08-23       Impact factor: 5.531

8.  A HCMV pp65 polypeptide promotes the expansion of CD4+ and CD8+ T cells across a wide range of HLA specificities.

Authors:  Maurizio Provenzano; Giovanni Sais; Laura Bracci; Adrian Egli; Maurizio Anselmi; Carsten T Viehl; Stefan Schaub; Hans H Hirsch; David F Stroncek; Francesco M Marincola; Giulio C Spagnoli
Journal:  J Cell Mol Med       Date:  2009-08       Impact factor: 5.295

9.  Whole blood assessment of antigen specific cellular immune response by real time quantitative PCR: a versatile monitoring and discovery tool.

Authors:  Elke Schultz-Thater; Daniel M Frey; Daniela Margelli; Nermin Raafat; Chantal Feder-Mengus; Giulio C Spagnoli; Paul Zajac
Journal:  J Transl Med       Date:  2008-10-16       Impact factor: 5.531

Review 10.  Potency analysis of cellular therapies: the emerging role of molecular assays.

Authors:  David F Stroncek; Ping Jin; Ena Wang; Betsy Jett
Journal:  J Transl Med       Date:  2007-05-30       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.